BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TScan Therapeutics\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies TScan Therapeutics\, Inc.'s drugs
  run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07702578-10829@assetmemo.bio
DTSTAMP:20261121T005942Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:TSC-101: Phase 3 readout est. (NCT07702578)
DESCRIPTION:TSC-101\, phase 3\, Hematologic Malignancies.\nStudy: A Study o
 f T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogene
 ic Peripheral Blood Stem Cell Transplantation\nEstimated primary completio
 n: June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tsc-101
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077
 02578
URL:https://assetmemo.bio/drug/tsc-101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
